Dionysus Digital Health

What Dionysus Digital Health does

Dionysus Digital Health, operating as Dionysus Healthcare, is a molecular diagnostics company developing AI and epigenetics-based blood tests for maternal mental health. Its sole commercial product, myLuma™, is described as the first prenatal blood test that predicts a woman's risk of postpartum depression as early as 28 weeks into pregnancy, with claimed predictive accuracy of up to 90% in validation studies. The company was founded in 2020, is headquartered in San Diego, and operates with 1-10 employees.

The underlying technology combines molecular diagnostics with AI-driven epigenetics analysis to interpret biomarkers from a standard prenatal blood draw, replacing the current standard of delayed, self-reported postpartum depression screening. Postpartum depression is positioned as the #1 complication of childbirth, with nearly a quarter of affected women reportedly receiving no treatment. The company targets two primary segments: healthcare providers and health systems (obstetricians, gynecologists, mental health providers) and expectant mothers at 28+ weeks of pregnancy seeking early risk assessment.

The business model centers on one-time diagnostic testing services sold to healthcare providers and health systems. The company is pre-commercial: commercial pilots of myLuma are scheduled for December 2025, FDA approval is targeted by 2027, and total funding to date is $14.5M in combined NIH and DoD grants, supplemented by accelerator investments from Springboard Enterprises and One Mind Accelerator. In November 2025, Rashmi Raghavendra was appointed CEO to lead the transition from validated science to commercial launch. Pricing has not been publicly disclosed.

Name

Dionysus Digital Health

Legal name

Dionysus Healthcare

Website

https://dionysushealth.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Dionysus Digital Health is a San Diego-based molecular diagnostics company developing myLuma™, an AI- and epigenetics-based prenatal blood test that predicts postpartum depression risk as early as 28 weeks into pregnancy, targeting obstetricians, health systems, and expectant mothers ahead of its December 2025 commercial pilot and 2027 FDA approval.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)

akta.pro secondary industries

Genetic & Prenatal Testing Laboratories (HLAFAMAH), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Maternal & High-Risk Pregnancy Remote Monitoring (BP, glucose, fetal/uterine monitoring) (HLALAFAG)

Keywords

• Molecular diagnostics
• Maternal mental health
• Prenatal blood testing
• Epigenetics diagnostics
• Postpartum depression screening

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Diagnostic Testing Services: Revenue derived from providing molecular diagnostic testing services to healthcare providers and health systems. The company delivers clinically validated diagnostics that replace delayed, self-reported screening with early, actionable insights.

Go-to-market motion2 records

Marketing channels1 record

Core offering

Dionysus Digital Health operates a molecular diagnostics platform whose flagship product, myLuma™, is the first prenatal blood test designed to predict postpartum depression risk as early as 28 weeks into pregnancy. The test uses an AI and epigenetics-based biomarker analysis to deliver up to 90% predictive accuracy, replacing delayed self-report screening with clinically validated diagnostics for expectant mothers served through OB-GYNs, maternal-fetal medicine specialists, and primary care providers.

Product overview

Dionysus Healthcare is a molecular diagnostics company offering a single unified product: myLuma™, the first prenatal blood test for predicting postpartum depression risk. The company is transitioning from validated science to commercial launch, with myLuma™ serving as its core offering focused on maternal mental health precision diagnostics. The product is designed for patients, providers, and health systems, delivering early actionable insights through blood test analysis at 28 weeks of pregnancy. Commercial pilots are planned for December 2025 with FDA approval expected by 2027.

Differentiator

Problem solved

Functional benefit

Brands

• myLuma™: The first prenatal blood test that predicts a woman's risk of postpartum depression as early as 28 weeks into pregnancy. Part of Dionysus Healthcare's molecular diagnostics platform for maternal mental health.

Products and services

• myLuma™ First-of-its-kind prenatal blood test that predicts postpartum depression risk as early as 28 weeks into pregnancy using an AI and epigenetics-based molecular diagnostics platform, delivering up to 90% predictive accuracy. It is offered to expectant mothers through OB-GYNs, maternal-fetal medicine specialists, and primary care providers, and is paid for by health systems as the contracting entity.

Quantifiable outcome

• Up to 90% predictive accuracy for postpartum depression
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature2 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Natera: Natera is a molecular diagnostics company best known for its non-invasive prenatal tests (NIPT) such as Panorama. It is directly comparable to Dionysus as a reproductive/prenatal diagnostics player selling molecular blood tests through OB/GYN and health system channels.
• BillionToOne: BillionToOne is a precision diagnostics company whose UNITY Fetal Antigen and other prenatal screening tests combine molecular biology with proprietary algorithms. It is directly comparable as a molecular diagnostics company launching novel blood-based tests into the prenatal care pathway.
• Myriad Genetics: Myriad Genetics is a genetic testing company with women's health offerings (e.g., Foresight carrier screen, Prequel NIPT). It is a comparable molecular diagnostics player targeting the same OB/GYN and reproductive health customer base, with established commercial infrastructure.

Emerging players

• Sema4 (now GeneDx): Sema4 (now operating under GeneDx) is a genomics and molecular diagnostics company with women's health and reproductive testing offerings. It is comparable as a specialized molecular diagnostics platform pursuing novel clinical claims, similar in stage trajectory to Dionysus.
• Progenity: Progenity was a molecular diagnostics company focused on reproductive health, prenatal testing, and women's health. It is comparable as an emerging player in the same maternal/prenatal diagnostics space that pursued a similar capital-constrained clinical-stage trajectory.

Broad incumbents

• Hologic: Hologic is a large women's health diagnostics and medical device company with established OB/GYN sales channels. It is comparable as a broad incumbent with overlapping women's health diagnostics capabilities that could expand into maternal mental health screening.
• LabCorp Diagnostics: LabCorp is one of the largest clinical reference laboratories in the US with deep OB/GYN and reproductive health testing menus. It is comparable as the broad incumbent clinical lab through which any new maternal diagnostic test would likely be distributed or to whom Dionysus could out-license.
• Quest Diagnostics: Quest Diagnostics is the largest US clinical reference laboratory with an extensive women's health and reproductive diagnostics menu. It is comparable as a broad incumbent that could develop or commercialize a competing maternal mental health assay at scale.
• Roche Diagnostics: Roche Diagnostics is a global IVD and molecular diagnostics leader with a women's health portfolio and dominant prenatal screening position. It is comparable as a broad incumbent that has the commercial and regulatory scale to enter maternal mental health risk prediction if the market validates.

Others

• Illumina: Illumina is the dominant next-generation sequencing platform provider whose technology underpins many molecular diagnostics. It is comparable as a key enabling infrastructure provider whose sequencing ecosystem could support or compete with epigenetic-based prenatal diagnostics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/DionysusHealth
• LinkedInlinkedin.com/company/dionysus-digital-health

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dionysus Digital Health